Inventor
BENDER JOHN A
US46 patents
⚠️ This page may combine multiple inventors who share the name “BENDER JOHN A”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
BRISTOL MYERS SQUIBB CO
22 patentsUS6476034B2Nov 5, 2002
Antiviral azaindole derivatives
BRISTOL MYERS SQUIBB CO103 citations98
US7994171B2Aug 9, 2011
Compounds for the treatment of hepatitis C
BRISTOL MYERS SQUIBB CO20 citations92
US7485633B2Feb 3, 2009
Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
BRISTOL MYERS SQUIBB CO20 citations92
US7473688B2Jan 6, 2009
Indolobenzazepine HCV NS5B inhibitors
BRISTOL MYERS SQUIBB CO26 citations92
US7456166B2Nov 25, 2008
Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
BRISTOL MYERS SQUIBB CO24 citations92
US6900323B2May 31, 2005
Antiviral azaindole derivatives
BRISTOL MYERS SQUIBB CO12 citations92
US6825201B2Nov 30, 2004
Indole, azaindole and related heterocyclic amidopiperazine derivatives
BRISTOL MYERS SQUIBB CO46 citations92
US6632819B1Oct 14, 2003
Antiviral azaindole derivatives
BRISTOL MYERS SQUIBB CO38 citations92
US8377980B2Feb 19, 2013
Hepatitis C virus inhibitors
BRISTOL MYERS SQUIBB CO22 citations91
US8048887B2Nov 1, 2011
Compounds for the treatment of hepatitis C
BRISTOL MYERS SQUIBB CO17 citations84
US7547690B2Jun 16, 2009
Compounds for the treatment of Hepatitis C
BRISTOL MYERS SQUIBB CO8 citations84
US7541353B2Jun 2, 2009
Compounds for the treatment of hepatitis C
BRISTOL MYERS SQUIBB CO11 citations84
US7541351B2Jun 2, 2009
Compounds for the treatment of hepatitis C
BRISTOL MYERS SQUIBB CO11 citations84
US7538102B2May 26, 2009
Compounds for the treatment of Hepatitis C
BRISTOL MYERS SQUIBB CO16 citations84
US7521443B2Apr 21, 2009
Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
BRISTOL MYERS SQUIBB CO13 citations84
US7521444B2Apr 21, 2009
Compounds for the treatment of hepatitis C
BRISTOL MYERS SQUIBB CO17 citations84
US7521441B2Apr 21, 2009
Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
BRISTOL MYERS SQUIBB CO18 citations84
US9776981B2Oct 3, 2017
Hepatitis C virus inhibitors
BRISTOL MYERS SQUIBB CO2 citations73
US9561212B2Feb 7, 2017
Hepatitis C virus inhibitors
BRISTOL MYERS SQUIBB CO3 citations73
US9340520B2May 17, 2016
Hepatitis C virus inhibitors
BRISTOL MYERS SQUIBB CO4 citations73
US7902204B2Mar 8, 2011
Diazaindole-dicarbonyl-piperazinyl antiviral agents
BRISTOL MYERS SQUIBB CO3 citations63
US8722688B2May 13, 2014
Compounds for the treatment of hepatitis C
BRISTOL MYERS SQUIBB CO2 citations62
BENDER JOHN A
7 patentsUS8552047B2Oct 8, 2013
Hepatitis C virus inhibitors
BENDER JOHN A6 citations83
US8618153B2Dec 31, 2013
Hepatitis C virus inhibitors
BENDER JOHN A6 citations72
US8796466B2Aug 5, 2014
Hepatitis C virus inhibitors
BENDER JOHN A3 citations62
US8431568B2Apr 30, 2013
Aromatic heterocyclic fused indolobenzadiazepine HCV NS5B inhibitors
BENDER JOHN A0 citations51
US8124601B2Feb 28, 2012
Compounds for the treatment of Hepatitis C
BENDER JOHN A1 citations51
US8138171B2Mar 20, 2012
Dioxolane and dioxolanone fused indolobenzadiazepine HCV NS5B inhibitors
BENDER JOHN A0 citations41
US8143244B2Mar 27, 2012
Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
BENDER JOHN A0 citations36
VIIV HEALTHCARE UK NO 5 LTD
4 patentsUS11505543B2Nov 22, 2022
4-oxo-3,4-dihydroquinazoline compounds as inhibitors of human immunodeficiency virus replication
VIIV HEALTHCARE UK NO 5 LTD3 citations72
US10954252B1Mar 23, 2021
Inhibitors of human immunodeficiency virus replication
VIIV HEALTHCARE UK NO 5 LTD6 citations70
US10035760B2Jul 31, 2018
Inhibitors of human immunodeficiency virus replication
VIIV HEALTHCARE UK NO 5 LTD0 citations40
US10221129B2Mar 5, 2019
Inhibitors of human immunodeficiency virus replication
VIIV HEALTHCARE UK NO 5 LTD0 citations38